HomeCompareQTEK vs ABBV

QTEK vs ABBV: Dividend Comparison 2026

QTEK yields 2666.67% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 QTEK wins by $148430280508.22M in total portfolio value
10 years
QTEK
QTEK
● Live price
2666.67%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$148430280508.33M
Annual income
$138,233,078,461,413,420.00
Full QTEK calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — QTEK vs ABBV

📍 QTEK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodQTEKABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, QTEK + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
QTEK pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

QTEK
Annual income on $10K today (after 15% tax)
$226,666.67/yr
After 10yr DRIP, annual income (after tax)
$117,498,116,692,201,400.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, QTEK beats the other by $117,498,116,692,180,350.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of QTEK + ABBV for your $10,000?

QTEK: 50%ABBV: 50%
100% ABBV50/50100% QTEK
Portfolio after 10yr
$74215140254.21M
Annual income
$69,116,539,230,719,096.00/yr
Blended yield
93.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

QTEK
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
-0.5
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

QTEK buys
0
ABBV buys
0
No recent congressional trades found for QTEK or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricQTEKABBV
Forward yield2666.67%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$148430280508.33M$102.3K
Annual income after 10y$138,233,078,461,413,420.00$24,771.77
Total dividends collected$147720561198.01M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: QTEK vs ABBV ($10,000, DRIP)

YearQTEK PortfolioQTEK Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$277,367$266,666.67$11,550$430.00+$265.8KQTEK
2$7,209,347$6,912,564.90$13,472$627.96+$7.20MQTEK
3$175,631,950$167,917,948.81$15,906$926.08+$175.62MQTEK
4$4,011,072,538$3,823,146,351.60$19,071$1,382.55+$4011.05MQTEK
5$85,892,595,210$81,600,747,594.12$23,302$2,095.81+$85892.57MQTEK
6$1,724,977,965,006$1,633,072,888,131.25$29,150$3,237.93+$1724977.94MQTEK
7$32,497,077,175,537$30,651,350,752,980.08$37,536$5,121.41+$32497077.14MQTEK
8$574,439,777,193,002$539,667,904,615,177.50$50,079$8,338.38+$574439777.14MQTEK
9$9,530,095,370,946,888$8,915,444,809,350,376.00$69,753$14,065.80+$9530095370.88MQTEK
10$148,430,280,508,326,560$138,233,078,461,413,420.00$102,337$24,771.77+$148430280508.22MQTEK

QTEK vs ABBV: Complete Analysis 2026

QTEKStock

QualTek Services Inc. provides communications infrastructure, power grid modernization, and renewable solutions to telecommunications and utilities industries in North America. The company operates through two segments, Telecom, and Renewables and Recovery Logistics. The Telecom segment engages in the installation, project management, maintenance, real estate, and site acquisition; fiber optic aerial and underground installation, fiber optic splicing, termination and testing, new installation, engineering, and fulfillment services to telecommunication companies; and electrical contracting, and utility construction and maintenance services to municipalities, electric membership cooperatives, and electric-utility companies. The Renewables and Recovery Logistics segment offers installation, testing, and maintenance for wind farms, solar farms, and fiber optic grids; continuity and disaster relief services to telecommunication and utility companies; and business-as-usual services, such as generator storage, and repair and cell maintenance services. The company was founded in 2012 and is headquartered in Blue Bell, Pennsylvania.

Full QTEK Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this QTEK vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

QTEK vs SCHDQTEK vs JEPIQTEK vs OQTEK vs KOQTEK vs MAINQTEK vs JNJQTEK vs MRKQTEK vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.